Marcel A. Muskiet

Leiden, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 90 publications

Safety and Tolerability of SGLT2 Inhibitors.

Safety and Tolerability of SGLT2 Inhibitors.

Journal: Handbook of experimental pharmacology

Published: August 12, 2026

Targeting kidney disease in type 1 diabetes: progress and promise.

Targeting kidney disease in type 1 diabetes: progress and promise.

Journal: Expert review of endocrinology & metabolism

Published: August 06, 2026

Response to the letter to the editor entitled "Glucodependence in Cardiorenometabolic Disease: Naming the Problem".

Response to the letter to the editor entitled "Glucodependence in Cardiorenometabolic Disease: Naming the Problem".

Journal: Kidney international reports

Published: July 10, 2026

The glucagon renaissance in obesity therapeutics.

The glucagon renaissance in obesity therapeutics.

Journal: The lancet. Diabetes & endocrinology

Published: July 07, 2026

Beyond insulin escalation: REIMAGINE 3 and advanced type 2 diabetes care.

Beyond insulin escalation: REIMAGINE 3 and advanced type 2 diabetes care.

Journal: Lancet (London, England)

Published: May 20, 2026

Relationship Between hsCRP, Glycaemic Control and Response to Sotagliflozin in Type 1 Diabetes: A Post Hoc Analysis of the inTandem3 Trial.

Relationship Between hsCRP, Glycaemic Control and Response to Sotagliflozin in Type 1 Diabetes: A Post Hoc Analysis of the inTandem3 Trial.

Journal: Diabetes, obesity & metabolism

Published: April 14, 2026

Mechanisms of SGLT inhibitor action and physiological mediators: systematic review and protocol for the MOSAIC collaborative meta-analysis.

Mechanisms of SGLT inhibitor action and physiological mediators: systematic review and protocol for the MOSAIC collaborative meta-analysis.

Journal: BMJ open

Published: February 26, 2026

Novel Therapeutic Strategies for Patients With CKD and Diabetes Mellitus.

Novel Therapeutic Strategies for Patients With CKD and Diabetes Mellitus.

Journal: Kidney international reports

Published: January 31, 2026

Effects of sotagliflozin on markers of volume status and sodium handling in patients with type 1 diabetes: A biomarker analysis of the inTandem3 clinical trial.

Effects of sotagliflozin on markers of volume status and sodium handling in patients with type 1 diabetes: A biomarker analysis of the inTandem3 clinical trial.

Journal: Diabetes, obesity & metabolism

Published: December 21, 2025

Semaglutide and cardiovascular risk in type 1 diabetes: A predictive modelling analysis in a double-blind, randomised, placebo-controlled cross-over trial.

Semaglutide and cardiovascular risk in type 1 diabetes: A predictive modelling analysis in a double-blind, randomised, placebo-controlled cross-over trial.

Journal: Diabetes, obesity & metabolism

Published: December 17, 2025

GLP-1, GIP, and Glucagon Excursions During a Mixed Meal Tolerance Test in Young and Lean South Asians Versus Europids.

GLP-1, GIP, and Glucagon Excursions During a Mixed Meal Tolerance Test in Young and Lean South Asians Versus Europids.

Journal: Diabetes, obesity & metabolism

Published: December 03, 2025

GLP-1, GIP, and Glucagon Excursions During a Mixed Meal Tolerance Test in Young and Lean South Asians Versus Europids.

GLP-1, GIP, and Glucagon Excursions During a Mixed Meal Tolerance Test in Young and Lean South Asians Versus Europids.

Journal: Diabetes, obesity & metabolism

Published: December 03, 2025

Showing 1-12 of 90

Last Updated: 09/26/2026